Pasithea Therapeutics

(NASDAQ) KTTA

Current Price$0.59

Market Cap$19.75M

Since IPO (2021)-99%

5 YearN/A

1 Year-29%

1 Month-25%

Pasithea Therapeutics Financials at a Glance

Market Cap

$19.75M

Revenue (TTM)

$0.00

Net Income (TTM)

-$19.73M

EPS (TTM)

-$2.07

P/E Ratio

-0.28

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.59

Volume

135,015

Open

$0.61

Price

$0.59

Volume

135,015

Open

$0.61

Previous Close

$0.59

Daily Range

$0.58 - $0.61

52-Week Range

$0.28 - $2.06

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.59

Volume

135,015

Open

$0.61

Previous Close

$0.59

Daily Range

$0.58 - $0.61

52-Week Range

$0.28 - $2.06

Estimated Earnings Date

Aug 13, 2026

KTTA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pasithea Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Tiago Reis Marques, MD, PhD

Website

www.pasithea.com

Headquarters

Miami Beach, FL 33139, US

KTTA Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-58%

Return on Capital

-40%

Return on Assets

-35%

Earnings Yield

-3.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.75M

Shares Outstanding

33.41M

Volume

135.01K

Avg. Volume

504.07K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$20.86M

EBITDA

-$20.19M

Operating Cash Flow

-$15.21B

Capital Expenditure

$0.00

Free Cash Flow

-$15.21B

Cash & ST Invst.

$55.16M

Total Debt

$0.00

Pasithea Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$157.54K

N/A

Gross Margin

0.00%

N/A

Market Cap

$19.75M

N/A

Market Cap/Employee

$4.94M

N/A

Employees

N/A

Net Income

-$2.87M

+19.5%

EBITDA

-$4.72M

-34.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$50.40M

+843.6%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-35.02%

N/A

Return on Invested Capital

-40.20%

N/A

Free Cash Flow

-$4.79M

-56.7%

Operating Cash Flow

-$4.79M

-56.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CYCNCyclerion Therapeutics, Inc.

CYCNCyclerion Therapeutics, Inc.$3.25+1.25%

PLRZPolyrizon Ltd.

PLRZPolyrizon Ltd.$11.13-3.89%

VYNEVYNE Therapeutics Inc.

VYNEVYNE Therapeutics Inc.$0.65-2.47%

QNRXQuoin Pharmaceuticals, Ltd.

QNRXQuoin Pharmaceuticals, Ltd.$4.20-10.64%

TCRTAlaunos Therapeutics, Inc.

TCRTAlaunos Therapeutics, Inc.$2.26+2.26%

VIVSVivoSim Labs, Inc.

VIVSVivoSim Labs, Inc.$1.14-1.72%

KALAKALA BIO, Inc.

KALAKALA BIO, Inc.$2.63+6.48%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98+0.02%

NOKNokia

NOKNokia$14.80+0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.59+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.52+0.02%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.46-0.05%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.04-0.02%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.02-0.00%

Questions About KTTA

What is the current price of Pasithea Therapeutics?

Pasithea Therapeutics is trading at $0.59 per share.

What is the 52-week range for Pasithea Therapeutics?

Over the past 52 weeks, Pasithea Therapeutics has traded between $0.28 and $2.06.

How much debt does Pasithea Therapeutics have?

As of the most recent reporting period, Pasithea Therapeutics reported total debt of $0.00.

How much cash does Pasithea Therapeutics have on hand?

Pasithea Therapeutics reported $50.50M in cash and cash equivalents in its most recent financial results.

What is Pasithea Therapeutics’s dividend yield?

Pasithea Therapeutics does not currently have a dividend yield.

Pasithea Therapeutics

Pasithea Therapeutics Financials at a Glance

KTTA News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Pasithea Therapeutics

KTTA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Pasithea Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About KTTA

What is the current price of Pasithea Therapeutics?

What is the 52-week range for Pasithea Therapeutics?

How much debt does Pasithea Therapeutics have?

How much cash does Pasithea Therapeutics have on hand?

What is Pasithea Therapeutics’s dividend yield?

Premium Investing Services